DE69910560D1 - Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga - Google Patents

Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga

Info

Publication number
DE69910560D1
DE69910560D1 DE69910560T DE69910560T DE69910560D1 DE 69910560 D1 DE69910560 D1 DE 69910560D1 DE 69910560 T DE69910560 T DE 69910560T DE 69910560 T DE69910560 T DE 69910560T DE 69910560 D1 DE69910560 D1 DE 69910560D1
Authority
DE
Germany
Prior art keywords
propofol
water
diisopropylphenol
analog
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69910560T
Other languages
English (en)
Other versions
DE69910560T2 (de
Inventor
S Hendler
A Sanchez
Jan Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
374Water Inc
Original Assignee
Vyrex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyrex Corp filed Critical Vyrex Corp
Publication of DE69910560D1 publication Critical patent/DE69910560D1/de
Application granted granted Critical
Publication of DE69910560T2 publication Critical patent/DE69910560T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
DE69910560T 1998-05-08 1999-05-07 Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga Expired - Lifetime DE69910560T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75356 1998-05-08
US09/075,356 US6254853B1 (en) 1998-05-08 1998-05-08 Water soluble pro-drugs of propofol
PCT/US1999/010013 WO1999058555A2 (en) 1998-05-08 1999-05-07 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues

Publications (2)

Publication Number Publication Date
DE69910560D1 true DE69910560D1 (de) 2003-09-25
DE69910560T2 DE69910560T2 (de) 2004-06-09

Family

ID=22125164

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69910560T Expired - Lifetime DE69910560T2 (de) 1998-05-08 1999-05-07 Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga

Country Status (9)

Country Link
US (1) US6254853B1 (de)
EP (1) EP1075489B1 (de)
JP (1) JP2002514656A (de)
AT (1) ATE247666T1 (de)
AU (1) AU765569B2 (de)
CA (1) CA2331371A1 (de)
DE (1) DE69910560T2 (de)
ES (1) ES2204126T3 (de)
WO (1) WO1999058555A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
CA2470500C (en) * 2001-12-28 2012-05-15 Guilford Pharmaceuticals, Inc. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US7312250B2 (en) 2002-03-12 2007-12-25 University Of Iowa Research Foundation Fluorine-substituted alkyl phenol compounds and their uses
PL373850A1 (en) * 2002-04-08 2005-09-19 Guilford Pharmaceuticals, Inc. Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE20215415U1 (de) * 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
JP2006518384A (ja) * 2003-01-31 2006-08-10 チルドレンズ・ホスピタル・ロス・アンジエルス 改善されたバイオアベイラビリティを有するフェンレチニドの経口組成物、およびその使用方法
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
US7230003B2 (en) * 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
WO2005033279A2 (en) * 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
AU2004286814A1 (en) * 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. pH sensitive prodrugs of 2,6-diisopropylphenol
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
DE602005010270D1 (de) * 2004-07-12 2008-11-20 Xenoport Inc Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
JP2008525501A (ja) * 2004-12-23 2008-07-17 ゼノポート，インコーポレイティド セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体
CA2598159A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
WO2006133506A1 (en) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
WO2007143038A1 (en) * 2006-05-30 2007-12-13 Trustees Of Columbia University In The City Of New York Method of mediating airway smooth muscle construction due to airway irritation
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
AU2007313639A1 (en) * 2006-10-31 2008-05-08 Mgp Biotechnologies, Inc. Butyrylcholinesterase inhibitors and their use in the treatment of neurodegenerative diseases
US9757399B2 (en) 2006-10-31 2017-09-12 Jal Therapeutics, Inc. Butyrylcholinesterase inhibitors
NZ580752A (en) 2007-05-09 2012-03-30 Pharmacofore Inc Stereoisomers propofol therapeutic compounds
CA2685813A1 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
US20090005444A1 (en) * 2007-06-21 2009-01-01 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
CN101575349B (zh) * 2009-06-11 2011-07-20 中国科学院广州化学研究所 一种丙泊酚磷酸酯二钠盐的制备方法
JP2011016777A (ja) * 2009-07-10 2011-01-27 Nipro Corp 新規システイン誘導体
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US9023813B2 (en) * 2011-04-13 2015-05-05 NuTek Pharma Ltd. Synthesis and use of glycoside derivatives of propofol
CN102382005B (zh) * 2011-09-08 2015-01-21 四川大学 含氨基羧酸酰胺结构的丙泊酚酯类衍生物、制备方法及其用途
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
WO2014180305A1 (zh) * 2013-05-09 2014-11-13 四川海思科制药有限公司 苯酚衍生物及其制备方法和在医药上的应用
US9643917B2 (en) 2014-02-17 2017-05-09 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Water-soluble propofol derivatives and uses thereof
PT3189834T (pt) * 2014-09-04 2024-03-15 Sichuan Haisco Pharmaceutical Co Ltd Utilização de agente de reforço do recetor gabaa na preparação de medicamento sedativo e anestésico
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
US11331271B2 (en) 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
CN107556167A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种麻醉类化合物及其制备方法和用途
NZ754168A (en) 2016-12-21 2024-08-30 Avecho Biotechnology Ltd Process for phosphorylating a complex alcohol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4839464A (de) * 1971-09-25 1973-06-09
US4170614A (en) * 1977-09-06 1979-10-09 Ppg Industries, Inc. Process for preparing halogenated diaryl hydrogen phosphates
DE3342109A1 (de) * 1983-11-18 1985-05-30 Toyo Jozo K.K., Tagata, Shizuoka Enzymatische pruefmethode
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5308874A (en) 1992-06-26 1994-05-03 Vyrex Corporation Airborne protectants against oxidative tissue damage
US5478857A (en) 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5529989A (en) * 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
IT1281876B1 (it) * 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Acido ialuronico e suoi derivati esterei per la preparazione di matrici per il rilascio controllato di farmaci.
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations

Also Published As

Publication number Publication date
WO1999058555A3 (en) 2000-03-02
ES2204126T3 (es) 2004-04-16
EP1075489A2 (de) 2001-02-14
WO1999058555A2 (en) 1999-11-18
DE69910560T2 (de) 2004-06-09
JP2002514656A (ja) 2002-05-21
AU3789499A (en) 1999-11-29
AU765569B2 (en) 2003-09-25
CA2331371A1 (en) 1999-11-18
US6254853B1 (en) 2001-07-03
ATE247666T1 (de) 2003-09-15
EP1075489B1 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
DE69910560D1 (de) Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
SE9502167L (sv) Insulinanalog-kompositioner
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
PT801564E (pt) Utilizacao de nebivolol como agente anti-aterogernico
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE69911401D1 (en) Immunoregulator
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
ATE311871T1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
BG101232A (en) Bactericides
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition